Replies to post #26415 on Relief Therapeutics Holding AG (RLFTF)

[nelskof]

The simple answer is we've only seen data on 21 patients that I am aware of.

I have to admit that had always been very discouraging to me because Dr Youssef, at Methodist, had worked with Said in the past trial on ARDS. It's always left me wondering why we were only seeing his work and was it placebo effect because he is a believer in VIP.

If they are indeed seeing these results in 150 patients, that would be fantastic news, and I can't wait until additional info is released. There has to be other investors like me that want to see more data on more patients than just Youssef's before going 'all in'.

[Veritas]

We've only seen data on the 21 patients from the open label study.

If we assume that there have not been additional patients added to the blinded study, and that it still stands at 102 enrollment, then there are an additional 27 patients from the Expanded Access Protocol that the company has data on. Javitt's quote from the press release yesterday about "similarly encouraging survival" having been observed must be referring to this group of up to 27 patients.

If anyone has a different take, please weigh in.